Warfarin Versus Aspirin in Patients With Atrial Fibrillation and Chronic Kidney Disease

A Randomized Controlled Prospective Trial of Warfarin Versus Aspirin for Stroke Prevention in Patients With Atrial Fibrillation and Chronic Kidney Disease

In this study, the investigators examine whether aspirin or warfarin is useful for atrial fibrillation patients with chronic kidney disease.

randomised open labelled prospective study

We enroll patients with CHADS2 score 1 non-valvular AF with chronic kidney disease, and analyze all thromboembolic event or major bleeding event during follow-up period. Warfarin group take dose adjusted warfarin (target INR 2.0-3.0) and aspirin group take aspirin 100mg daly.

Thromboembolic events: Ischemic stroke or systemic arterial occlusion Major bleeding: gastrointestinal bleeding or intracranial bleeding (code 430, code 431, code 432 by ICD-9-CM codes)

-> Only the first event of each case will be used for the analysis

Inclusion Criteria:

• CHADS2 score 1 nonvalvular atrial fibrillation patients with chronic kidney disease

Exclusion Criteria:

• HAS-BLED ≥30
• History of syncope or seizure within 1 year
• History of major bleeding event within 6 months
• BP>180/100
• Abnormal prothrombin time
• Hypersensitivity of aspirin or warfarin
• Folstein mini mental state examination score <26
• Taking or had taken other anticoagulants